Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
about
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLCCombination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination.
P2860
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@en
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@nl
type
label
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@en
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@nl
prefLabel
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@en
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@nl
P2093
P2860
P356
P1476
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
@en
P2093
Bruce Acres
Gisele Lacoste
Jean-Marc Limacher
P2860
P356
10.1007/82_2015_429
P577
2015-02-22T00:00:00Z